Western Financial Corp CA Has $3.46 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Western Financial Corp CA raised its holdings in Eli Lilly and Company (NYSE:LLY) by 0.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,909 shares of the company’s stock after acquiring an additional 34 shares during the quarter. Eli Lilly and Company comprises 2.0% of Western Financial Corp CA’s portfolio, making the stock its 6th largest position. Western Financial Corp CA’s holdings in Eli Lilly and Company were worth $3,464,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of LLY. Lynx Investment Advisory bought a new position in Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC bought a new position in shares of Eli Lilly and Company during the second quarter worth $36,000. Redmont Wealth Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $40,000. Morton Brown Family Wealth LLC raised its stake in Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the period. Finally, Cedar Mountain Advisors LLC lifted its holdings in Eli Lilly and Company by 53.3% during the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after acquiring an additional 16 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Barclays increased their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Guggenheim upped their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Bank of America lifted their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,002.24.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $906.13 on Tuesday. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The firm has a 50-day moving average price of $921.65 and a two-hundred day moving average price of $859.57. The company has a market capitalization of $861.19 billion, a P/E ratio of 133.45, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.